Galectin Therapeutics/GALT

$1.88

5.61%
-
1D1W1MYTD1YMAX

About Galectin Therapeutics

Galectin Therapeutics Inc. is a clinical-stage biotechnology company. The Company is engaged in drug research and development to create new therapies for fibrotic disease, cancer and selected other diseases. The Company’s drug candidates are based on its method of targeting galectin proteins, which are key mediators of biologic and pathologic functions. The Company’s product candidates include galectin-3 inhibitor, which is a belapectin and GM-CT-01. The Company’s lead drug belapectin is a carbohydrate-based drug that inhibits the galectin-3 protein which is directly involved in multiple inflammatory, fibrotic, and malignant diseases. The Company is using a galectin-3 inhibitor to treat advanced liver fibrosis and liver cirrhosis in non-alcoholic steatohepatitis (NASH) patients. The Company also designed a Phase IIb/III clinical study, the NAVIGATE trial, evaluating the safety and efficacy of its galectin-3 inhibitor, belapectin, for the prevention of esophageal varices.
Ticker
GALT
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology & Drugs
CEO
Joel Lewis
Employees
12
Headquarters
Norcross, United States

GALT Metrics

BasicAdvanced
$116.28M
Market cap
-
P/E ratio
-$0.76
EPS
0.81
Beta
-
Dividend rate

What the Analysts think about GALT

Analyst Ratings

Majority rating from 1 analysts.
Buy

Price Targets

Average projection from 1 analysts.
485.11% upside
High $11.00
Low $11.00
$1.88
Current price
$11.00
Average price target

GALT Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$0
-
Net income
$-10.4M
14.29%
Profit margin
0%
-

GALT Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 50%
QuarterlyAnnual
Q4 22
Q1 23
Q2 23
Q3 23
Q4 23
Actual
-$0.18
-$0.19
-$0.15
-$0.24
-
Expected
-$0.17
-$0.21
-$0.21
-$0.16
-$0.16
Surprise
5.88%
-9.52%
-28.57%
50%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Galectin Therapeutics stock

Buy or sell Galectin Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing